High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation

Highlights • Ovarian carcinomas arising in BRCA1/2 germ-line mutation carriers show high sensitivity to platinum-based neoadjuvant therapy. • Chemonaive hereditary ovarian cancers frequently demonstrate somatic loss of the wild-type BRCA1 allele. • Platinum therapy results in a rapid selection of tu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2015-12, Vol.369 (2), p.363-367
Hauptverfasser:	Gorodnova, Tatiana V, Sokolenko, Anna P, Ivantsov, Alexandr O, Iyevleva, Aglaya G, Suspitsin, Evgeny N, Aleksakhina, Svetlana N, Yanus, Grigory A, Togo, Alexandr V, Maximov, Sergey Ya, Imyanitov, Evgeny N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged BRCA1 Breast cancer Cancer therapies Chemotherapy Cloning Family medical history Female Genes, BRCA1 Germ-Line Mutation - genetics Hematology, Oncology and Palliative Medicine Humans Loss of heterozygosity (LOH) Metastasis Middle Aged Mutation Neoadjuvant therapy Neoadjuvant Therapy - methods Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Response rates Studies Surgery Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Ovarian carcinomas arising in BRCA1/2 germ-line mutation carriers show high sensitivity to platinum-based neoadjuvant therapy. • Chemonaive hereditary ovarian cancers frequently demonstrate somatic loss of the wild-type BRCA1 allele. • Platinum therapy results in a rapid selection of tumor cell clones with restored heterozygous BRCA1 status.
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2015.08.028